Literature DB >> 16091254

Immune-based therapies: an adjunct to antiretroviral treatment.

Jeffrey M Jacobson1.   

Abstract

Combination antiretroviral therapy potently suppresses HIV replication, but does not eradicate the infection. Drug resistance and long-term toxicities limit its use. The recovery of general immune function is often not complete. Immune-based therapies have the potential to boost HIV-specific immunity and reduce the need for antiretroviral drugs, and to promote general immune competence in situations in which antiretroviral treatment alone is inadequate. Strategies to reduce the immunopathogenic consequences of HIV infection with immunomodulating therapies are conceivable. Ultimately, eradication of the infection will require methods to target the latent memory T-cell reservoir of virus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091254     DOI: 10.1007/s11904-005-0024-4

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  63 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Authors:  Joseph Kulkosky; Giuseppe Nunnari; Miguel Otero; Sandra Calarota; Geetha Dornadula; Hui Zhang; Anne Malin; Julie Sullivan; Yan Xu; Joseph DeSimone; Timothy Babinchak; John Stern; Winston Cavert; Ashley Haase; Roger J Pomerantz
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

3.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.

Authors:  Leonard H Calabrese; Michael M Lederman; John Spritzler; Robert W Coombs; Lawrence Fox; Barbara Schock; Belinda Yen-Lieberman; Ronald Johnson; Donna Mildvan; Namita Parekh
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

5.  Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.

Authors:  Laura A Napolitano; Joan C Lo; Michael B Gotway; Kathleen Mulligan; Jason D Barbour; Diane Schmidt; Robert M Grant; Robert A Halvorsen; Morris Schambelan; Joseph M McCune
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

6.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

7.  Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.

Authors:  Yoshitsugu Kojima; Ke-Qin Xin; Takaaki Ooki; Kenji Hamajima; Tomohiro Oikawa; Kaori Shinoda; Tomomi Ozaki; Yuka Hoshino; Nao Jounai; Masatoshi Nakazawa; Dennis Klinman; Kenji Okuda
Journal:  Vaccine       Date:  2002-07-26       Impact factor: 3.641

8.  Early reduction of immune activation in lymphoid tissue following highly active HIV therapy.

Authors:  J Andersson; T E Fehniger; B K Patterson; J Pottage; M Agnoli; P Jones; H Behbahani; A Landay
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

View more
  1 in total

1.  Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues.

Authors:  Melissa J Churchill; Paul R Gorry; Daniel Cowley; Luxshimi Lal; Secondo Sonza; Damian F J Purcell; Katherine A Thompson; Dana Gabuzda; Justin C McArthur; Carlos A Pardo; Steven L Wesselingh
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.